Exelixis
EXEL
#1855
Rank
NZ$18.48 B
Marketcap
NZ$68.67
Share price
-2.18%
Change (1 day)
15.38%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2025 (TTM): NZ$1.50 Billion

According to Exelixis's latest financial reports the company's current earnings are NZ$2.28 Billion. In 2024 the company made an earning of NZ$1.13 Billion, an increase over its 2023 earnings that were of NZ$0.42 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$1.50 B32.89%
2024 NZ$1.13 B164.69%
2023 NZ$0.42 B9.89%
2022 NZ$0.38 B-20.33%
2021 NZ$0.48 B124.82%
2020 NZ$0.21 B-67.14%
2019 NZ$0.66 B-11.94%
2018 NZ$0.75 B185.09%
2017 NZ$0.26 B-325.82%
2016 -NZ$0.12 Billion-58.12%
2015 -NZ$0.28 Billion-37.61%
2014 -NZ$0.45 Billion9.75%
2013 -NZ$0.41 Billion65.96%
2012 -NZ$0.25 Billion-291.63%
2011 NZ$0.12 B-195.59%
2010 -NZ$0.14 Billion-42.17%
2009 -NZ$0.24 Billion-18.98%
2008 -NZ$0.29 Billion-6.99%
2007 -NZ$0.31 Billion46.3%
2006 -NZ$0.21 Billion33.25%
2005 -NZ$0.16 Billion-30.92%
2004 -NZ$0.23 Billion44.29%
2003 -NZ$0.16 Billion12.86%
2002 -NZ$0.14 Billion22.79%
2001 -NZ$0.12 Billion60.14%
2000 -NZ$71.17 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
NZ$53.79 B 3,609.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$19.67 B 1,257.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$13.68 B 844.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$15.11 B 942.07%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$38.33 B 2,544.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$13.33 B 819.85%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$15.47 B 967.56%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-NZ$54.06 Million-103.73%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-NZ$48.22 Million-103.33%๐Ÿ‡บ๐Ÿ‡ธ USA